Skip to main content

Table 3 Comparison of safety endpoints according to the treatment received (n = 100)

From: Efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure with volume overload: a prospective, randomized, controlled clinical trial

Safety endpoint

Early ultrafiltration

group (n = 40)

Torasemide plus tolvaptan

group (n = 60)

Before treatment

After treatment

Before treatment

After treatment

Heart rate (beats/min)

85.25 ± 18.37

84.20 ± 14.32

82.02 ± 14.65

82.72 ± 15.78

Systolic blood pressure (mmHg)

124.98 ± 19.14

128.40 ± 19.55

128.40 ± 19.55

129.12 ± 18.69

Diastolic blood pressure (mmHg)

68.63 ± 11.04

67.38 ± 10.07

71.93 ± 11.28

68.62 ± 10.38

Respiratory rate (beats/min)

20.28 ± 2.89

21.68 ± 3.53

19.67 ± 2.61

20.22 ± 3.29

Serum sodium (mmol/L)

137.12 ± 22.20

142.23 ± 4.66

141.37 ± 3.85

142.50 ± 4.06

Serum potassium (mmol/L)

4.03 ± 0.72

4.06 ± 0.54

3.83 ± 0.63

3.95 ± 0.55

Serum creatinine (μmol/L)

155.70 ± 72.05

154.27 ± 88.46

128.30 ± 82.66

126.57 ± 75.92

Access-site ecchymosis (N)

–

2

–

–

Access-site infection (N)

–

0

–

–

Major bleedings (N)

–

0

–

–

  1. Data values are presented as the mean ± SD. For all comparisons between the two treatments, P was n.s